Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus SALURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus SALURON.
HYDROCHLOROTHIAZIDE INTENSOL vs SALURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
Saluron (hydroflumethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water. It also reduces peripheral vascular resistance through direct vasodilatory effects.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
Initial: 50-100 mg orally once daily; maintenance: 50-200 mg orally once daily or in divided doses.
None Documented
None Documented
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged in renal impairment (up to 24-36 hours with creatinine clearance <30 mL/min).
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Primarily renal (≥95%) via glomerular filtration and tubular secretion; approximately 70% as unchanged drug, 25% as metabolites. Biliary/fecal excretion accounts for <5%.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic